Literature DB >> 19577166

Plasma cell myeloma.

Pei Lin1.   

Abstract

Plasma cell myeloma is a heterogenous disease with variable clinical presentation and outcome. The prognosis is largely determined by tumor biology. Newer therapeutic agents are rapidly changing the survival outlook of myeloma patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19577166     DOI： 10.1016/j.hoc.2009.04.012

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  5 in total

1.  Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.

Authors:  Tae-Dong Jeong; Chan-Jeoung Park; Hyoeun Shim; Seongsoo Jang; Hyun-Sook Chi; Dok Hyun Yoon; Dae-Young Kim; Jung-Hee Lee; Je-Hwan Lee; Cheolwon Suh; Kyoo Hyung Lee
Journal:  Korean J Hematol       Date:  2012-12-24

2.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

3.  GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.

Authors:  Zachary D Crees; Keith Stockerl-Goldstein; Abi Vainstein; Hemda Chen; John F DiPersio
Journal:  Future Oncol       Date:  2019-09-09       Impact factor: 3.404

4.  Extramedullary plasmacytoma presenting as a solitary mass in the intracranial posterior fossa.

Authors:  Mohammad Hossein Daghighi; Masoud Poureisa; Mohammad Shimia; Ramin Mazaheri-Khamene; Shadi Daghighi
Journal:  Iran J Radiol       Date:  2012-11-20       Impact factor: 0.212

5.  Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling.

Authors:  Riddhi Jaiswal; Garima Agarwal; Sudhir Singh
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.